Alzheimer's disease (AD) presents a complex pathology entangling numerous pathological factors, including amyloid-β (Aβ), metal ions, and reactive oxygen species (ROS). Increasing evidence reveals pathological connections among these distinct components in AD. For instance, the association between the amyloid cascade and metal ion hypotheses has introduced a novel pathogenic target: metal-bound Aβ. Investigation of such interconnections requires substantial research and can be expedited by chemical reagents that are able to modify multiple pathogenic factors in AD. Drug repurposing is an efficient approach for rediscovering previously utilized molecules with desirable biological and pharmaceutical properties as chemical reagents. Herein, we report the evaluation of three pre-approved drug molecules, selected based on their chemical structure and properties, as chemical reagents that can be used for elucidating the complicated pathology of AD.

阿尔茨海默病 (AD) 呈现出一种复杂的病理学，其中包括多种病理因素，包括淀粉样蛋白-β (Aβ)、金属离子和活性氧 (ROS)。越来越多的证据揭示了 AD 中这些不同成分之间的病理联系。例如，淀粉样蛋白级联和金属离子假说之间的关联引入了一个新的致病靶点：金属结合的 Aβ。对这种相互联系的调查需要大量研究，并且可以通过能够改变 AD 中多种致病因素的化学试剂来加速。药物再利用是一种有效的方法，用于重新发现以前使用的具有所需生物和药物特性的分子作为化学试剂。在此，我们报告了对三种预先批准的药物分子的评估，